From Analysis:
Entorhinal cortex layer II vulnerability in Alzheimer's disease
Why are entorhinal cortex layer II neurons among the earliest and most selectively vulnerable cell populations in Alzheimer's disease?
These hypotheses emerged from the same multi-agent debate that produced this hypothesis.
Lateral EC layer II receives direct projections from olfactory bulb mitral/tufted cells. Environmental toxicants (PM2.5, metals, VOCs) enter the brain via olfactory epithelium and propagate retrogradely along olfactory nerves to layer II, driving neuroinflammation, oxidative stress, and NLRP3 inflammasome activation. This creates a unique exposure profile that primes layer II for accelerated tau pathology. However, mechanistic validation is limited and environmental exposure models have poor human translation.
No AI visual card yet
Mechanism: Layer II stellate cells exhibit intrinsic regenerative firing properties driven by T-type (Cav3.2) calcium channels that produce low-threshold plateau potentials and rhythmic bursting at theta frequencies (~5 Hz). This generates sustained intracellular Ca²⁺ transients that chronically activate calpains, impair ubiquitin-proteasome function, and accelerate tau hyperphosphorylation at AD-relevant
Specificity problem. T-type calcium channels (Cav3.2 and related subtypes) are expressed throughout the brain, including thalamic relay neurons, inferior olive cells, and other neuronal populations that do not show equivalent vulnerability in AD. If Cav3.2 upregulation is the primary driver, why are layer II stellate cells uniquely susceptible? The hypothesis does not adequately explain regional specificity—
Of the seven proposed mechanisms for entorhinal cortex (EC) layer II vulnerability, four merit serious clinical development consideration based on druggability, biomarker readiness, and translational feasibility. The T-type calcium channel hypothesis (H1) and NPTX2 replacement (H6) represent the most near-term intervention opportunities given existing pharmacologic tools. The mTOR-autophagy axis (H7) offers a mechanistically distinct but overlapping target with rapamycin-
No clinical trials data available
neurodegeneration | 2026-04-02 | archived
No comments yet. Be the first to comment!